Research on Predicting the Efficacy of Immunotherapy for Non-small Cell Lung Cancer Based on CT Radiomics and Peripheral Blood Inflammatory Markers
Technology in Cancer Research & Treatment · 2026-07 · 25
DOI: 10.1177/15330338261465744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 03.07.2026. Verfasst von Xinyuan Wen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tomography, X-Ray Computed, Immunotherapy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Anhui Provincial Special Project for Clinical Medical Research Translation.
Abstract (Originalsprache)
Introduction
We developed and validated predictive models based on CT radiomics and peripheral blood inflammatory markers to predict immunotherapy response in non-small cell lung cancer (NSCLC).
Methods
This retrospective study included 128 NSCLC patients receiving anti–PD-1/PD-L1 monotherapy as second-line therapy between January 2020 and January 2024. All eligible patients who met the inclusion criteria during the study period were consecutively included to minimize selection bias. Baseline non-contrast and contrast-enhanced chest CT acquired within 15 days before immunotherapy initiation was used for radiomics. Patients were randomly split into training and testing cohorts (7:3). Radiomics features were extracted and selected using LASSO with cross-validation followed by MRMR. A radiomics model, a clinical model (inflammatory markers), and a combined nomogram model were developed. Model performance was assessed by AUC and calibration; clinical utility was evaluated by decision curve analysis. Reporting followed TRIPOD+AI guidelines.
Results
The combined model achieved the best performance (AUC 0.8802, 95% CI 0.8106–0.9497 in the training cohort; AUC 0.7329, 95% CI 0.5679–0.8979 in the testing cohort), outperforming the clinical model (AUC 0.6481 and 0.5325) and the radiomics model (AUC 0.7878 and 0.5621). DeLong tests for pairwise AUC comparisons yielded P values of 0.243 and 0.478, respectively.
Conclusions
The combined clinical–radiomics model may help identify NSCLC patients more likely to respond to immunotherapy. External validation is required before clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- Graduate School of Bengbu Medical University, Bengbu, China.
ORCID-Profile: Yichuan Ma
Förderung
- Anhui Provincial Special Project for Clinical Medical Research Translation
Zitieren
APA
Wen, X., Li, Y., Hu, Y., Chen, A., Wang, K., Zou, W., Xie, B., & Ma, Y. (2026). Research on Predicting the Efficacy of Immunotherapy for Non-small Cell Lung Cancer Based on CT Radiomics and Peripheral Blood Inflammatory Markers. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261465744
Vancouver
Wen X, Li Y, Hu Y, Chen A, Wang K, Zou W, et al. Research on Predicting the Efficacy of Immunotherapy for Non-small Cell Lung Cancer Based on CT Radiomics and Peripheral Blood Inflammatory Markers. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261465744
BibTeX
@article{Wen2026,
author = {Wen, Xinyuan and Li, Yihan and Hu, Yindi and Chen, Aiqi and Wang, Kai and Zou, Wentao and Xie, Bo and Ma, Yichuan},
title = {Research on Predicting the Efficacy of Immunotherapy for Non-small Cell Lung Cancer Based on CT Radiomics and Peripheral Blood Inflammatory Markers},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261465744}
}
EUVIMED